This is the authors' abstract. We don't add key points for this paper.
7570 Background: Daratumumab (Dara)-based regimens have resulted in deep responses and improved outcomes in newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). As the use of dara has increased in both settings, understanding the utility of retreating patients (pts) with dara-based therapy is important. Our prior work showed that pts treated with dara-based induction can derive benefit from dara-based retreatment. Herein, we examined outcomes of dara-based retreatment (D2) in pts with RRMM. Methods: We conducted a retrospective study of pts with RRMM who received D2 at Memorial Sloan Kettering from 1/1/2015 to 12/31/2021. Cutoff date for analysis was 1/9/2024. Pts who received ³1 cycle of dara-based therapy as the initial dara-based regimen (D1) and D2 were included. Response was assessed by IMWG response criteria. Discrete pt characteristics were summarized by frequency (%) and continuous characteristics were summarized by median (Interquartile Range, IQR). Progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier method. Results: In 128 RRMM pts who received D2, median age at start of D2 was 66 (IQR 59-73); 50% male; 17% Black; ISS Stage I 45%, II 35%, III 19%; and 44% had high-risk cytogenetics (gain/amp 1q, t(4;14), t(14;16), t(14;20), del(17p)). Median prior lines of therapy (LOT) at D1 was 3 (range 2-10) and at D2 was 5 (3-14). Median time between end of D1 and start of D2 was 7.3 months (IQR 3-15.6). Of 119 pts with dara-refractory status, 100 were dara-refractory at D2. Overall response rate (ORR) was 54% for D1 and 51% for D2 for response-evaluable pts. Median duration of therapy for D2 was 4.7 months (1.8-11.3) and median time to next treatment for D2 was 8.2 months (5.8-11.4). After a median follow-up (mFU) of 56.4 months from start of D2, median PFS (mPFS) for D2 was 8.2 months (95%CI 5.3-11.2) and median OS was 43 months (35.8-60.3). Subgroup analysis based on retreatment interval of 180 days (>180 days N=74) demonstrated no significant difference in PFS between pts who received D2 ≤180 days or >180 days from D1. Median PFS from start of D2 was 8.2 months (95%CI 3.9-19.3) for ≤180-days cohort and 7.6 months (5.3-11.5) for >180-days cohort (P=0.35). When comparing outcomes of pts who received D2 as ≤4 LOTs and >4 LOTs, the mPFS for pts who received D2 as >4 LOTs was 5.4 months compared to 13.9 months for pts who received D2 as ≤4 LOT (P=0.002). Conclusions: In this retrospective study, dara retreatment yielded similar ORR compared to initial dara-based therapy in RRMM, despite a large proportion of pts being dara-refractory prior to D2. Our findings suggest that retreatment with dara in combination with other active MM agents can generate responses in pts with RRMM who are dara-refractory.[Table: see text]
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: